Adezmapimod
Adezmapimod (SB203580) is a selective pyridinyl imidazole p38alpha/beta MAPK inhibitor that blocks stress-activated MAPK signalling, inflammatory cytokine production (TNF-alpha, IL-1beta), and MAPKAP-K2 phosphorylation. Used extensively as a research tool for dissecting stress-activated signalling pathways, inflammatory cascades, and drug resistance mechanisms across a wide range of cancer models.
Description
Scientific Overview: Adezmapimod (SB203580) is a selective pyridinyl imidazole p38alpha/beta MAPK inhibitor that blocks stress-activated MAPK signalling, inflammatory cytokine production (TNF-alpha, IL-1beta), and MAPKAP-K2 phosphorylation. Used extensively as a research tool for dissecting stress-activated signalling pathways, inflammatory cascades, and drug resistance mechanisms across a wide range of cancer models.
Mechanism of Action: p38 MAPK (p38alpha/beta) Inhibitor
Purity: ≥99% | Molecular Formula: C21H16FN3OS
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | p38 MAPK (p38alpha/beta) Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C21H16FN3OS |
| CAS Number | 152121-47-6 |
